A limited number of drugs are approved by the regulatory authorities which can be classified into two main categories: (1) acetylcholinesterase inhibitors, which prevent the break-down of the neurotransmitter acetylcholine into choline and acetate and are approved to treat mild to moderate dementia, and (2) glutamatergic antagonists, which are intended to protect nervous tissue against glutamate-mediated excitotoxicity [3]. Here, ACHE is linked to dementia.